These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16516473)

  • 1. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL
    Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
    Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
    Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
    J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
    Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
    ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
    Kitano Y; Suzuki T; Kawahara E; Yamazaki T
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Substituted-[1,4]dioxano[2,3-g]quinazolines as inhibitors of epidermal growth factor receptor kinase.
    Lee JY; Park YK; Seo SH; Yang BS; Park H; Lee YS
    Arch Pharm (Weinheim); 2002 Dec; 335(10):487-94. PubMed ID: 12506397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial transport study.
    Sun HY; Guan S; Bi HC; Su QB; Huang WL; Chowbay B; Huang M; Chen X; Li CG; Zhou SF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jul; 854(1-2):320-7. PubMed ID: 17467348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
    El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
    Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors.
    Lee YS; Seo SH; Yang BS; Lee JY
    Arch Pharm (Weinheim); 2005 Oct; 338(10):502-5. PubMed ID: 16211656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lüth A; Löwe W
    Eur J Med Chem; 2008 Jul; 43(7):1478-88. PubMed ID: 17981366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
    Li RD; Zhang X; Li QY; Ge ZM; Li RT
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.